Monitoring choroidal blood flow in patients with central serous chorioretinopathy
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
This study is trying to see how blood flow in the eye affects the healing of fluid buildup in people with central serous chorioretinopathy and how it changes with treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Helse Stavanger HF Government |
| Locations | 1 site (Stavanger) |
| Trial ID | NCT05589974 on ClinicalTrials.gov |
What this trial studies
This observational study aims to monitor patients with central serous chorioretinopathy (CSC) using advanced imaging techniques such as laser speckle flow graphy, swept source optical coherence tomography, and swept source optical coherence tomography angiography. The research focuses on understanding the relationship between choroidal blood flow characteristics and the resolution of subretinal fluid in acute CSC, as well as the changes in blood flow in response to treatment in chronic CSC. By investigating these factors, the study seeks to provide insights into the pathophysiological mechanisms of the disease and identify potential biomarkers for disease activity and treatment response.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with either acute central serous chorioretinopathy lasting less than four months or chronic central serous chorioretinopathy lasting four months or more.
Not a fit: Patients with a history of retinal diseases other than CSC or contraindications for specific imaging techniques or treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of central serous chorioretinopathy, potentially enhancing treatment outcomes for patients.
How similar studies have performed: While this approach is focused on specific imaging techniques in CSC, similar studies have shown promise in understanding choroidal circulation in other retinal conditions, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:- * Able to sign informed consent * Possible to obtain fundus imaging * Acute CSC ˂4 months of duration in one eye, defined as: 1. Subfoveal presence of SRF on OCT 2. Present attack is 1st -3rd attack of CSC b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT * Chronic CSC ≥4 months of duration in one eye, defined as: 1. Subfoveal presence of SRF on OCT 2. Subjective visual loss/symptoms 3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT 4. Patient history and examination consistent with chronic CSC Exclusion Criteria: * History of retinal disease other than CSC (e.g. retinal detachment) * Contraindications for FA, ICGA or PDT (only for chronic CSC)
Where this trial is running
Stavanger
- Stavanger University Hospital, Department of Ophthalmology — Stavanger, Norway (Recruiting)
Study contacts
- Principal investigator: Vegard Forsaa, MD PhD — Helse Stavanger HF
- Study coordinator: Vegard Forsaa, MD PhD
- Email: forsaa@gmail.com
- Phone: +4748152212
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.